|Mr. Ilan Danieli||Founder, Pres, CEO & Director||263.8k||N/A||1972|
|Mr. Carl R. Iberger||CFO & Sec.||208.16k||N/A||1953|
|Mr. Ahmed Zaki Sabet||Chief Operating Officer||163.69k||N/A||1986|
|Mr. Douglas Sites||VP of Sales||N/A||N/A||N/A|
|Mr. Ayman Mohamed||Sr. VP of R&D and Laboratory Operations||N/A||N/A||1985|
Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients worldwide. It has partnership agreements with the Yale School of Medicine, Dana-Farber Cancer Institute, Inc. and other institutions specializing in cancer research, diagnostics, and treatment; and development agreement with H3 Biomedicine to create a targeted gene panel. The company is based in New Haven, Connecticut.
Precipio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.